Article Information
PubMed
Published By
History
- Received September 15, 2016
- Revision received January 30, 2017
- Accepted February 6, 2017
- First published February 20, 2017.
- Version of record published March 22, 2017.
Copyright & Usage
Copyright © 2017 the authors 0270-6474/17/373202-13$15.00/0
Author Information
Author contributions
Author contributions: H.H.D., L.N.E., D.M.S., and A.Z.M. designed research; H.H.D., L.N.E., D.M.S., and A.Z.M. performed research; H.H.D. and A.Z.M. analyzed data; H.H.D. and A.Z.M. wrote the paper.
Disclosures
- Received September 15, 2016.
- Revision received January 30, 2017.
- Accepted February 6, 2017.
This work was supported by the National Institutes of Health (Grant DA16272 to A.Z.M.) (−)-Morphine sulfate and (+)-naloxone were kindly provided by the National Institute on Drug Abuse drug supply program. We thank Lauren Hanus and Alyssa Bartlett for technical assistance.
The authors declare no competing financial interests.
- Correspondence should be addressed to Anne Z. Murphy, Neuroscience Institute, Georgia State University, 100 Piedmont Ave, SE, Atlanta, GA 30303. amurphy{at}gsu.edu
Other Version
- previous version (February 20, 2017).
- You are viewing the most recent version of this article.
